人民财讯8月15日电，普洛药业（000739）在互动平台表示，公司与多家全球领先的宠物药公司建立了 长期、密切的合作关系，截至目前，公司已有49个宠物药项目，项目数量和销售收入均保持持续增长态 势。 ...

Policy Support - Shenzhen has introduced 32 policy measures to support the entire pharmaceutical and medical device industry chain, focusing on areas such as preclinical research, clinical trials, registration approval, production, and market application [1][2] - The measures emphasize support for emerging technologies and new business models, including "AI+" in pharmaceuticals, biomanufacturing, cell and gene therapy, pet pharmaceuticals, rare disease drugs, and traditional Chinese medicine [1][2] Financial Incentives - The measures provide significant financial rewards for innovative drug development, offering up to 30 million yuan for successful clinical trials of Class 1 innovative drugs [2] - Financial support for pet pharmaceuticals includes rewards of 300,000 yuan, 200,000 yuan, and 100,000 yuan for different categories of new veterinary drugs, with a cap of 500,000 yuan per enterprise annually [2] Clinical Trial Enhancements - Shenzhen aims to establish an international clinical trial center in the Greater Bay Area, optimizing clinical trial processes to reduce internal approval times to within 25 weeks [3] - The measures support the integration of innovative drugs and medical devices, expanding the "Hong Kong-Macau Drug and Device Pass" to include more medical institutions [3] Infrastructure Development - Shenzhen plans to allocate at least 200,000 square meters of industrial land and 1 million square meters of specialized parks annually, focusing on "AI+ pharmaceuticals" and synthetic biology [3] - Key areas like Guangming Science City and Pingshan National Bio-Industry Base will develop an ecosystem combining parks and platforms with public service facilities [3] Talent Acquisition - The measures include a global talent recruitment plan targeting high-level professionals in cell and gene therapy, with a focus on creating a favorable environment for talent development [4] - Innovations in the clinical research talent evaluation system will incorporate research achievements into promotion criteria, alongside housing and education support [4]

Core Viewpoint - Shenzhen has introduced 32 policy measures to support the development of the pharmaceutical and medical device industries, aiming to create a complete industrial ecosystem covering basic research, clinical translation, production, and market application [1][2]. Policy Support - The measures focus on the entire chain of pharmaceutical and medical device development, including preclinical research, clinical trials, registration, production, and market promotion, with special support for emerging technologies such as "AI+" in pharmaceuticals, biomanufacturing, and rare disease drugs [2][3]. - Significant financial incentives are provided for innovative drug development, with rewards of up to 30 million yuan for successful clinical trials and market entry of class 1 innovative drugs [2]. AI and Biomanufacturing - Shenzhen aims to promote the application of artificial intelligence in biomanufacturing and drug development, focusing on drug target discovery, drug design, and safety analysis, while supporting the establishment of major public service platforms for AI in drug development [3]. Clinical Trial Efficiency - The establishment of the Greater Bay Area International Clinical Trial Center is prioritized to optimize clinical trial resources and processes, aiming to reduce the internal time for initiating clinical trials to within 25 weeks [4]. - The measures also include expanding the "Hong Kong-Macao Drug and Device Pass" to facilitate the import of urgently needed medical products [4]. Talent Acquisition - Shenzhen plans to implement a global talent recruitment program focusing on high-level professionals in cell and gene therapy, with innovative evaluation systems for clinical research talent linked to career advancement [5].